Pharmaceuticals最新文献

{"title":"Therapeutic Monitoring of Vancomycin and Factors Affecting Survival in ICU Patients with Infections.","authors":"Nadezhda G Berdnikova, Dmitry V Tsyganko, Vladislav D Vasiukov, Vladimir S Arnautov, Aleksei V Trofimov, Valerii A Menshov, Evgeniy S Melnikov, Evgenia V Shikh, Susanna S Sologova, Elena A Smolyarchuk, Natalia B Lazareva","doi":"10.3390/ph19081303","DOIUrl":"10.3390/ph19081303","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Vancomycin remains a cornerstone antibiotic for Gram-positive infections, but its narrow therapeutic window and marked pharmacokinetic variability in critical patients complicate dosing. This study aimed to analyze survival and identify factors associated with mortality in intensive care unit (ICU) patients receiving vancomycin under therapeutic drug monitoring (TDM). <b>Methods:</b> A single-center, retrospective cohort study was conducted at City Clinical Hospital named after I.V. Davydovsky (Moscow, Russia) between December 2021 and January 2026 (IRB protocol VANCO-2021). A total of 190 adult patients from surgical, therapeutic, and cardiac ICUs receiving vancomycin for at least 3-5 days were analyzed; trough concentrations were determined by HPLC-MS/MS. Cox proportional hazards, spline Cox, and segmented (piecewise) Cox models were applied to identify mortality predictors, with bootstrap subsampling assessing threshold robustness. <b>Results:</b> Three independent predictors of mortality were identified: ln(minimum vancomycin concentration) (HR = 1.644, <i>p</i> = 0.028), age (HR = 1.019, <i>p</i> = 0.037), and serum creatinine (HR = 1.004, <i>p</i> < 0.001). A data-driven threshold trough concentration (Ctrough) of 25.5 µg/mL was identified, above which mortality increased substantially (63.0% vs. 26.4%; <i>p</i> < 0.05). The adjusted hazard ratio for Ctrough ≥ 25.5 µg/mL was approximately 1.88 (<i>p</i> = 0.054); bootstrap subsampling yielded an uncertainty interval of 23.2-33.6 µg/mL. <b>Conclusions:</b> Elevated minimum vancomycin concentrations exceeding 25.5 µg/mL are independently and statistically associated with increased mortality in ICU patients, likely reflecting altered drug exposure and illness severity rather than a direct causal effect. Systematic TDM is essential for maintaining vancomycin within the therapeutic range.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System.","authors":"Francisco Arias-Aragón, Carmen Mata-Martín, Alba Sánchez-Redondo, Jesús Novalbos, Miguel Ángel Seguido, Francisco Abad-Santos, Mar Hernaez, Mercè Brunet, David Hansoe Heredero-Jung, Alejandro de la Sota-Pérez, María Isidoro-García, Almudena Gil-Rodriguez, Alba Barral-Raña, Olalla Maroñas, Gladys Guadalupe Olivera Pasquini, Enrique G Zucchet, María José Herrero, José Manuel Dodero-Anillo, Alicia Alba Máñez, María José Pedrosa-Martínez, Adrián Llerena, On Behalf Of The BioFRAM PGx Consortium","doi":"10.3390/ph19081305","DOIUrl":"10.3390/ph19081305","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Pharmacogenetics (PGx) may improve drug safety and effectiveness, but its integration into routine care remains heterogeneous across the Spanish National Health System (NHS). This article presents BioFRAM PGx, a multicentre implementation framework that defines the methodological and operational basis for subsequent observational validation in cardiovascular and mental-health care settings. <b>Methods:</b> The framework was developed by healthcare centres from eight Spanish Autonomous Communities through a structured review of PharmGKB/ClinPGx clinical annotations, CPIC and DPWG guidelines, and national regulatory resources. Gene-drug pairs were prioritized according to clinical actionability, therapeutic relevance, applicability to the Spanish population, and analytical feasibility. BioFRAM PGx defines a panel of seven pharmacogenes and 35 drugs, standardized genotyping and phenotype-assignment procedures, pharmacovigilance and clinical variables, healthcare-resource measures, and centralized data management. The proposed non-interventional validation phase includes adults receiving at least one selected drug in hospital or primary-care settings, with a minimum six-month follow-up. PGx results are not returned to clinicians and do not modify treatment. Its primary objective is to assess the predictive value of PGx genotyping for adverse drug reactions (ADRs); secondary objectives include ADR incidence and implementation feasibility. <b>Results:</b> The main outputs are the proposed multicentre observational design, the prioritized gene-drug panel, harmonized analytical and pharmacovigilance workflows, standardized data domains, and a centralized data-management strategy. No patient-level clinical, implementation, or economic outcomes are presented. <b>Conclusions:</b> BioFRAM PGx provides a structured multicentre framework for harmonizing pharmacogenetic procedures across the Spanish NHS. Its clinical effectiveness, influence on prescribing, scalability, and economic outcomes remain to be assessed in subsequent studies.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure-Guided Immunoinformatics for the Rational Design of a Multi-Epitope Vaccine Against Batai Orthobunyavirus.","authors":"Maha Abdullah Alwaili, Nawal Al-Hoshani, Huda A Alqahtani, Rasha Alonaizan, Khaled Alzhrani, Tariq Aziz","doi":"10.3390/ph19081307","DOIUrl":"10.3390/ph19081307","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Batai orthobunyavirus (BATV) is an emerging mosquito-borne zoonotic pathogen for which no licensed vaccine is currently available. The viral envelope glycoprotein plays an important role in viral attachment and host immune recognition, making it a potential target for rational vaccine design. <b>Methods:</b> In this study, an immunoinformatics-based framework was used to design and evaluate a multi-epitope vaccine candidate targeting the BATV envelope glycoprotein. Selected B-cell, cytotoxic T-lymphocyte (CTL), and helper T-lymphocyte (HTL) epitopes were assembled using appropriate linkers and a human β-defensin adjuvant. Population coverage and in silico immune simulations were conducted to evaluate the potential breadth and magnitude of immune response. <b>Results:</b> The final vaccine construct demonstrated favorable physicochemical characteristics, high predicted antigenicity (0.7959), and non-allergenic properties while maintaining favorable predicted structural characteristics and broad predicted population coverage (99.92%). Structural docking revealed a stable interaction between the vaccine construct and human TLR4, with a weighted docking score of -1194.8, suggesting favorable molecular recognition and receptor engagement. Normal Mode Analysis further supported the structural stability and conformational integrity of the vaccine receptor complex. Immune simulation predicted robust primary and secondary immune responses characterized by elevated IgM and IgG antibody production, sustained memory cell formation, and strong IFN-γ and IL-2 responses, indicating the potential to elicit balanced humoral and cellular immunity. <b>Conclusions:</b> This study presents a structurally optimized and validated multiepitope vaccine candidate against the emerging Batai orthobunyavirus. These computational findings identified a promising vaccine candidate for further investigation; however, its immunogenicity, safety, and protective efficacy before further vaccine development can be considered.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copper/Copper Oxide Nanoparticles: Biological Synthesis, Characterization and Potential Biomedical Applications: Advances and Perspectives.","authors":"Md Amdadul Huq, Md Ashikur Rahman, Md Rasel Rana, Jong-Whi Park","doi":"10.3390/ph19081306","DOIUrl":"10.3390/ph19081306","url":null,"abstract":"<p><p>The biosynthesis of copper and copper oxide nanoparticles (Cu/CuO-NPs) has attracted considerable interest due to its non-toxic, eco-friendly nature and wide-ranging applications, especially in nanomedicine and biomedical fields. Traditional nanoparticle production methods often involve toxic chemicals and generate harmful byproducts. In contrast, biological synthesis provides a cleaner, safer, more cost-effective, and sustainable alternative. Various biological sources, including plants, bacteria, fungi, and yeast, have been employed for the efficient and non-toxic production of Cu/CuO-NPs. These organisms contain diverse biomolecules such as enzymes, proteins, amino acids, vitamins, flavonoids, and alkaloids that function as reducing, capping, and stabilizing agents during nanoparticle formation. The biologically synthesized Cu/CuO-NPs are characterized using UV-VIS spectroscopy, Raman spectroscopy, TEM, SEM, EDX, XRD, TGA, XPS, FTIR, DLS, zeta potential analyzer, etc. Cu/CuO-NPs hold promise for applications in nanomedicine, primarily because of their strong antimicrobial and anticancer activities and potential use as disinfectants against infectious diseases. Various reports have suggested that the biologically synthesized Cu/CuO-NPs have exhibited significant antimicrobial and anticancer efficacies against pathogenic bacteria, fungi and viruses and various cancer cells. Due to their nanoscale dimensions and extensive surface area, Cu/CuO nanoparticles can readily infiltrate cell walls, disrupt membrane integrity, generate reactive oxygen species, and hinder both DNA replication and protein production, leading to cell death. The present review comprehensively describes the biological synthesis of Cu/CuO-NPs, their characterization techniques, and potential antibacterial, antifungal, antiviral, and anticancer applications. The modes of action for antibacterial, antifungal, antiviral, and anticancer properties have also been explored critically.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence.","authors":"Michał Janiak, Katarzyna Mądra-Gackowska, Lidia Wydeheft, Marcin Gackowski","doi":"10.3390/ph19081298","DOIUrl":"10.3390/ph19081298","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Oral small-molecule inhibitors of activated factor XI (FXIa) are intended to attenuate thrombosis with less disruption of hemostasis than established anticoagulants, but clinical outcomes have not consistently paralleled pharmacodynamic target engagement. This systematic review integrated molecular design, preclinical pharmacology, human pharmacokinetics/pharmacodynamics (PK/PD), and clinical outcomes to identify where translation is maintained or lost. <b>Methods:</b> The review followed PRISMA 2020 and PRISMA-S and was registered in PROSPERO (CRD420261356169). PubMed/MEDLINE, Scopus, and Web of Science Core Collection were searched from inception through 30 March 2026 and rerun on 11 August 2026, with a final publication-eligibility cut-off of 30 June 2026. Owing to heterogeneity, evidence was synthesized narratively. <b>Results:</b> Sixty-eight eligible reports were included, comprising seven randomized parent outcome trials and nine reports with in vivo thrombosis or bleeding experiments. In the OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% with asundexian versus 8.4% with placebo (HR 0.74, 95% CI 0.65-0.84), while major bleeding was 1.9% versus 1.7% (HR 1.10, 95% CI 0.85-1.44). In OCEANIC-AF, stroke or systemic embolism occurred in 1.3% with asundexian versus 0.4% with apixaban (HR 3.79, 95% CI 2.46-5.83), despite less major bleeding (0.2% vs. 0.7%; HR 0.32, 95% CI 0.18-0.55). <b>Conclusions:</b> Oral small-molecule FXIa inhibition is pharmacologically coherent, but clinical benefit is indication-, comparator-, and background-therapy-dependent. PD markers confirm target engagement but are not validated efficacy surrogates; hard clinical outcomes remain decisive.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiofilm Substantivity of AgNPs in Clinical Oral Biofilms from Patients with Motor and Intellectual Disabilities: An In Vitro and Exploratory Study.","authors":"Carolina Holguín-Meraz, Rita Elizabeth Martínez-Martínez, Erasto Armando Zaragoza-Contreras, Rubén Abraham Domínguez-Pérez, Karla Lizette Tovar-Carrillo, Alejandro Donohue-Cornejo, Juan Carlos Cuevas-González, Simón Yobanny Reyes-López, Erika de Lourdes Silva-Benítez, María Verónica Cuevas-González, León Francisco Espinosa-Cristóbal","doi":"10.3390/ph19081299","DOIUrl":"10.3390/ph19081299","url":null,"abstract":"<p><p><b>Background</b>: Motor and intellectual disabilities (MIDs) belong to a restricted and vulnerable social group with health restrictions for maintaining and preserving adequate oral health. Silver nanoparticles (AgNPs) have appeared as an encouraging therapy due to their excellent antimicrobial effects; however, scientific information on the antimicrobial effectiveness of AgNPs against bacteria in patients with MIDs remains limited. This study aimed to evaluate the antimicrobial substantivity of AgNPs in oral bacteria from patients with and without MIDs. <b>Methods</b>: Fifty-four oral biofilm samples were obtained from 26 participants with MIDs and 28 participants without MIDs. The microbial inhibition activity and the antimicrobial substantivity of AgNPs were determined. The antibiofilm activity of the AgNPs was explored using scanning electron microscopy (SEM). <b>Results</b>: The AgNPs displayed uniform size distributions (9.8 ± 1.7 nm) and electrical charges in surface particles that limit particle clustering (-39.8 ± 3.3 mV). The AgNPs were more effective than chlorhexidine (CHX) in eliminating bacteria from oral biofilms derived from both MID and non-MID patients (<i>p</i> < 0.05); therefore, the antimicrobial substantivity of the AgNPs was statistically better than deionized water but lower than CHX at specific exposure times (<i>p</i> < 0.05). The antimicrobial effectiveness of AgNPs at even low concentrations was associated with the type of oral biofilm, the type of antimicrobial solution, and, in some cases, gender. SEM images indicate a clear alteration in oral biofilm structure when AgNPs were applied. <b>Conclusions</b>: AgNPs exhibited significant potential to limit oral bacterial proliferation from microbial biofilms while contributing to the maintenance of oral condition in individuals with MIDs.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"D/PVA/I-1 as an Antibiotic Adjuvant: In Vitro Synergy and Membrane Permeabilization in MDR Bacteria.","authors":"Ardak Jumagaziyeva, Seitzhan Turganbay, Anar Seisembekova, Daniil Shepilov, Zhanar Iskakbayeva, Sabina Kenesheva, Saltanat Jumabayeva, Gaukhar Askhatkyzy, Nurdaulet Temir, Abdurashit Khamidulin, Alexandr Ilin","doi":"10.3390/ph19081300","DOIUrl":"10.3390/ph19081300","url":null,"abstract":"<p><p><b>Background:</b> Antimicrobial resistance (AMR) is among the most pressing challenges in modern infectious medicine, driving progressive failure of standard antibacterial therapy and rising mortality from infections caused by multidrug-resistant (MDR) pathogens. Antibiotic potentiation through adjuvant compounds capable of restoring the activity of existing drugs represents a promising strategy to overcome resistance without developing fundamentally new antibacterial molecules. This study aimed to evaluate the antibiotic-potentiating activity of a dextrin/polyvinyl alcohol/iodine complex (D/PVA/I-1), developed at the Scientific Center for Anti-Infectious Drugs JSC (Almaty, Kazakhstan), against clinically relevant MDR reference strains. <b>Methods:</b> Nine reference strains, <i>Staphylococcus aureus</i> (ATCC 33591, BAA-39), <i>Escherichia coli</i> (ATCC BAA-196, BAA-2523), <i>Klebsiella pneumoniae</i> (ATCC BAA-2524, 700603), <i>Acinetobacter baumannii</i> (ATCC BAA-1790), <i>Streptococcus pneumoniae</i> (ATCC BAA-660), and <i>Haemophilus influenzae</i> (ATCC 33930), and two clinical isolates, <i>P. aeruginosa</i> SCAID PHRX1-2019 and <i>E. coli</i> SCAID WND1-2021, were tested. Antibiotic-potentiating activity was assessed by checkerboard assay with calculation of the fractional inhibitory concentration index (FICI); bactericidal kinetics were evaluated by time-kill analysis. The effect of D/PVA/I-1 on cytoplasmic membrane permeability was investigated using a crystal violet uptake assay. <b>Results:</b> Of 45 D/PVA/I-1-antibiotic combinations tested across nine antibiotics, synergy (FICI ≤ 0.5) was demonstrated in 44.4% of cases, partial synergy in 48.9%, and additive effects in 6.7%; no antagonistic interactions were detected. The most pronounced potentiating effect occurred against Gram-positive pathogens, particularly MRSA strains (66.7% synergistic combinations). Time-kill analysis confirmed suppression of the regrowth phenotype characteristic of MDR strains under monotherapy and restoration of bactericidal activity against antibiotics to which strains exhibited intrinsic resistance. D/PVA/I-1 induced a dose- and time-dependent increase in membrane permeability in both Gram-positive and Gram-negative organisms. <b>Conclusions:</b> D/PVA/I-1 is an effective broad-spectrum antibiotic potentiator and represents a promising basis for combination therapy regimens against MDR infections.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Plant-Derived Compounds on the Cervical Spinal Cord After Sciatic Nerve Transection in Diabetic Rats.","authors":"Abdullah Hilmi Marangoz, Burcu Delibaş, Gamze Altun, Arife Ahsen Kaplan, Hala Mahgoub Hamour, Abit Aktaş, Sait Polat, Süleyman Kaplan","doi":"10.3390/ph19081301","DOIUrl":"10.3390/ph19081301","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Diabetes mellitus is known to exacerbate neural degeneration and impair regenerative capacity following injury. This study aimed to investigate the effects of <i>Garcinia kola</i> and curcumin on spinal cord morphology and neural structure in a diabetic sciatic nerve injury model. <b>Methods</b>: Spinal cord tissues were obtained from male Wistar albino rats subjected to sciatic nerve transection and diabetes induction in a previously established experimental model. Animals had been assigned to five experimental groups (<i>n</i> = 7 per group): control group, transected sciatic nerve group, transected sciatic nerve + diabetes mellitus (DM), transected sciatic nerve + diabetes mellitus + curcumin (DM + Cur), and transected sciatic nerve + diabetes mellitus + <i>Garcinia kola</i> (DM + GK). Curcumin (300 mg/kg/day) and <i>Garcinia kola</i> (200 mg/kg/day) were administered orally. All animals were sacrificed at three months post-injury. Cervical (C3-C5) spinal cord segments were processed for histological evaluation, and quantitative assessments were performed using unbiased stereological methods to estimate neuronal and structural parameters. Microscopic analyses were conducted to assess morphological alterations. <b>Results</b>: Diabetes combined with sciatic nerve transection induced marked structural alterations in the spinal cord, including reductions in neuronal density and disruption of tissue organization. The DM group showed a significantly lower number of motor neurons than the other groups; similarly, it showed a significant decrease in soma area compared to the Cont and Sham groups. <b>Conclusions</b>: Both the curcumin and <i>Garcinia kola</i> treatment groups exhibited partial preservation of spinal cord morphology. This study provides evidence that <i>Garcinia kola</i> and curcumin exert protective effects not only at the peripheral nerve level, but also in the spinal cord following diabetic nerve injury.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148830735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Tber et al. Pyrido[2',1':2,3]imidazo[4,5-<i>c</i>]isoquinolin-5-amines as Potential Cytotoxic Agents Against Human Neuroblastoma. <i>Pharmaceuticals</i> 2021, <i>14</i>, 750.","authors":"Zahira Tber, Mohammed Loubidi, Jabrane Jouha, Ismail Hdoufane, Mümin Alper Erdogan, Luciano Saso, Güliz Armagan, Sabine Berteina-Raboin","doi":"10.3390/ph19081297","DOIUrl":"10.3390/ph19081297","url":null,"abstract":"<p><p><b>Error in Figures</b> [...].</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Intravenous Magnesium on Postoperative Pain and Analgesic Outcomes in Patients Undergoing General Anesthesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Lucyna Tomaszek, Wioletta Mędrzycka-Dąbrowska, Sandra Lange, Sebastian Dąbrowski, Mateusz Szczupak","doi":"10.3390/ph19081296","DOIUrl":"10.3390/ph19081296","url":null,"abstract":"<p><p><b>Background:</b> Intravenous magnesium sulfate has been proposed as an adjuvant analgesic in perioperative care; however, its effects on postoperative pain and related analgesic outcomes remain uncertain. <b>Methods:</b> A systematic search of the literature was conducted from 1 January 2015 through 19 January 2026 to identify randomized controlled trials comparing intravenous magnesium sulfate with placebo in adults undergoing general anesthesia. Pain intensity was harmonized to a 0-10 scale. Primary outcomes were early postoperative pain (0-6 h), pain at 12 h, and pain at 24 h. Secondary outcomes were postoperative opioid consumption, expressed as intravenous morphine equivalents, and time to first rescue analgesia. Random-effects meta-analyses were performed. Risk of bias was assessed using RoB 2, and certainty of evidence using GRADE. <b>Results:</b> A total of 24 randomized controlled trials were included in the qualitative synthesis, of which 22 provided data for quantitative meta-analysis, yielding 23 comparisons and a total of 1750 participants. Intravenous magnesium reduced early postoperative pain (mean difference [MD] -0.90, 95% confidence interval [CI] -1.33 to -0.47; I² = 96.27%) and pain at 24 h (MD -0.59, 95% CI -1.00 to -0.18; I² = 66.36%), but not pain at 12 h (MD -0.52, 95% CI -1.15 to 0.11; I² = 77.38%). Magnesium also reduced postoperative opioid consumption (MD -6.28 mg morphine equivalents, 95% CI -8.94 to -3.61; I² = 95.93%) and prolonged time to first rescue analgesia (MD 85.61 min, 95% CI 40.11 to 131.10; I² = 79.37%). Certainty of evidence ranged from very low to moderate, with the highest certainty observed for pain at 24 h. <b>Conclusions:</b> Intravenous magnesium was associated with reduced postoperative pain, particularly at 24 h, and with opioid-sparing effects. However, substantial heterogeneity across outcomes and generally low-to-moderate certainty of evidence warrant cautious interpretation. Magnesium may be considered as part of multimodal analgesia in appropriately selected patients.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"19 8","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13516737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}